SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aziyo Biologics, Inc. (AZYO) trades at a trailing P/E of 1.2. Trailing earnings yield is 86.21%.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (1.2); analyst target implies upside (+587.9%); earnings yield beats bond yields (86.21%).
- Trailing Earnings Yield 86.21% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $10.25 (+587.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 71/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AZYO
Valuation Multiples
P/E (TTM)1.2
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio5.57
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.29
Book Value / Share$0.00
Revenue / Share$0.27
FCF / Share$0.00
Yields & Fair Value
Earnings Yield86.21%
Dividend Yield0.00%
Analyst Target$10.25 (+587.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-1.83 |
$39.04M |
$-11.57M |
-29.6% |
| 2019 |
$-1.82 |
$42.9M |
$-11.94M |
-27.8% |
| 2020 |
$-2.13 |
$42.68M |
$-21.83M |
-51.1% |
| 2021 |
$-2.38 |
$47.39M |
$-24.83M |
-52.4% |
| 2022 |
$-2.38 |
$49.19M |
$-32.9M |
-66.9% |
| 2024 |
$-1.86 |
$24.38M |
$-53.95M |
-221.3% |
| 2025 |
$1.29 |
$12.29M |
$53.38M |
434.2% |
